Herpes simplex virus type 2: Epidemiology and management options in developing countries

Sexually Transmitted Infections

Volumn 83, Issue 1, 2007, Pages 16-22

  Paz Bailey, G ^a,b   Ramaswamy, M ^d   Hawkes, S J ^c   Geretti, A M ^d  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; HERPES VACCINE; VIRUS VACCINE;

ANTIVIRAL THERAPY; CONDOM; DIAGNOSTIC PROCEDURE; GENITAL HERPES; GENITAL ULCER; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LABORATORY DIAGNOSIS; LOWEST INCOME GROUP; MEDLINE; PREVALENCE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; REVIEW; SERODIAGNOSIS; VIRUS DETECTION; VIRUS TRANSMISSION;

EID: 33847173711     PISSN: 13684973     EISSN: None     Source Type: Journal    
DOI: 10.1136/sti.2006.020966     Document Type: Review

References (77)

1. World Health Organization. Herpes simplex virus type 2 programmatic and research priorities in developing countries, WHO/HIV_AIDS/2001.05. Report of a WHO/UNAIDS/LSHTM Workshop, 14-10 February 2001, London.
2. Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines 2002, 51.
3. World Health Organization. Guidelines for the management of sexually transmitted infections, Revised version. WHO/RHI/01.10 2003. Geneva: WHO, 2003.
4. Fleming DT, McQuillan GM, Johnson RE, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997;337:1105-11.
5. Pebody RG, Andrews N, Brown D, et al. The seroepidemiology of herpes simplex virus type 1 and 2 in Europe. Sex Transm Infect 2004;80:185-91.
6. Weiss H. Epidemiology of herpes simplex virus type 2 infection in the developing world. Herpes 2004;11:A24-35.
7. Paz-Bailey G, Rahman M, Chen C, et al. Changes in the etiology of sexually transmitted diseases in Botswana between 1993 and 2002: implications for the clinical management of genital ulcer disease. Clin Infect Dis 2005;41:1304-12.
8. Plummer FA, D'Costa LJ, Nsanze H, et al. Clinical and microbiologic studies of genital ulcers in Kenyan women. Sex Transm Dis 1985;12:193-7.
9. Greenblatt RM, Lukehart SA, Plummer FA, et al. Genital ulceration as a risk factor for human immunodeficiency virus infection. AIDS 1988;2:47-50.
10. Ndinya-Achola JO, Kihara AN, Fisher LD, et al. Presumptive specific clinical diagnosis of genital ulcer disease in a primary health care setting in Nairobi. Int J STD AIDS 1996;7:201-5.
11. Malonza IM, Tyndall MW, Ndinya-Achola JO, et al. A randomized, double-blind, placebo-controlled trial of single-dose ciprofloxacin versus erythromycin for the treatment of chancroid in Nairobi, Kenya. J Infect Dis 1999;180:1886-93.
12. Morse SA, Trees DL, Htun Y, et al. Comparison of clinical diagnosis and standard laboratory and molecular methods for the diagnosis of genital ulcer disease in Lesotho: association with human immunodeficiency virus infection. J Infect Dis 1997;175:583-9.
13. Behets FM, Liomba G, Lule G, et al. Sexually transmitted diseases and human immunodeficiency virus control in Malawi: a field study of genital ulcer disease. J Infect Dis 1995;171:451-5.
14. Hoyo C, Hoffman I, Moser BK, et al. Improving the accuracy of syndromic diagnosis of genital ulcer disease in Malawi. Sex Transm Dis 2005;32:231-7.
15. Behets FM, Andriamiadana J, Randrianasolo D, et al. Chancroid, primary syphilis, genital herpes, and lymphogranuloma venereum in Antananarivo, Madagascar. J Infect Dis 1999;180:1382-5.
16. Bogaerts J, Ricart CA, Van Dyck E, et al. The etiology of genital ulceration in Rwanda. Sex Transm Dis 1989;16:123-6.
17. Bogaerts J, Kestens L, van Dyck E, et al. Genital ulcers in a primary health clinic in Rwanda: impact of HIV infection on diagnosis and ulcer healing (1986-1992). Int J STD AIDS 1998;9:706-10.
18. Totten PA, Kuypers JM, Chen CY, et al. Etiology of genital ulcer disease in Dakar, Senegal, and comparison of PCR and serologic assays for detection of Haemophilus ducreyi. J Clin Microbiol 2000;38:268-73.
19. Dangor Y, Bollard RC, da L Exposto F, et al. Accuracy of clinical diagnosis of genital ulcer disease. Sex Transm Dis 1990;17:184-9.
20. Lai W, Chen CY, Morse SA, et al. Increasing relative prevalence of HSV2 infection among men with genital ulcers from a mining community in South Africa. Sex Transm Infect 2003;79:202-7.
21. Chen CY, Bollard RC, Beck-Sague CM, et al. Human immunodeficiency virus infection and genital ulcer disease in South Africa: the herpetic connection. Sex Transm Dis 2000;27:21-9.
22. Coovadia YM, Kharsany A, Hoosen A. The microbial aetiology of genital ulcers in black men in Durban, South Africa. Genitourin Med 1985;61:266-9.
23. O'Farrell N, Hoosen AA, Coetzee KD, et al. Genital ulcer disease in men in Durban, South Africa. Genitourin Med 1991;67:327-30.
24. O'Farrell N, Hoosen AA, Coetzee KD, et al. Genital ulcer disease in women in Durban, South Africa. Genitourin Med 1991;67:322-6.
25. Moodley P, Sturm PD, Connolly C, et al. Identification of women at high STD risk among STD clinic attendees: implications for STD programmes. Int J STD AIDS 2003;14:526-31.
26. Ahmed HJ, Mbwana J, Gunnarsson E, et al. Etiology of genital ulcer disease and association with human immunodeficiency virus infection in two tanzanian cities. Sex Transm Dis 2003;30:114-19.
27. Mwansasu A, Mwakagile D, Haarr L, et al. Detection of HSV-2 in genital ulcers from STD patients in Dar es Salaam, Tanzania. J Clin Virol 2002;24:183-92.
28. Mabey DC, Wall RA, Bello CS. Aetiology of genital ulceration in the Gambia. Genitourin Med 1987;63:312-15.
29. Kamya MR, Nsubuga P, Grant RM, et al. The high prevalence of genital herpes among patients with genital ulcer disease in Uganda. Sex Transm Dis 1995;22:351-4.
30. Gray RH, Wawer MJ, Sewankambo NK, et al. Relative risks and population attributable fraction of incident HIV associated with symptoms of sexually transmitted diseases and treatable symptomatic sexually transmitted diseases in Rakai District, Uganda. Rakai Project Team. AIDS 1999;13:2113-23.
31. Risbud A, Chan-Tack K, Gadkari D, et al. The etiology of genital ulcer disease by multiplex polymerase chain reaction and relationship to HIV infection among patients attending sexually transmitted disease clinics in Pune, India. Sex Transm Dis 1999;26:55-62.
32. Zainah S, Cheong YM, Sinniah M, et al. A microbiological study of genital ulcers in Kuala Lumpur. Med J Malaysia 1991;46:274-82.
33. Beyrer C, Jitwatcharanan K, Natpratan C, et al. Molecular methods for the diagnosis of genital ulcer disease in a sexually transmitted disease clinic population in northern Thailand: predominance of herpes simplex virus infection. J Infect Dis 1998;178:243-6.
34. Sanchez J, Volquez C, Totten PA, et al. The etiology and management of genital ulcers in the Dominican Republic and Peru. Sex Transm Dis 2002;29:559-67.
35. Behets FM, Brathwaite AR, Hylton-Kong T, et al. Genital ulcers: etiology, clinical diagnosis, and associated human immunodeficiency virus infection in Kingston, Jamaica. Clin Infect Dis 1999;28:1086-90.
36. Korenromp EL, Bakker R, De Vlas SJ, et al. Can behavior change explain increases in the proportion of genital ulcers attributable to herpes in sub-Saharan Africa? A simulation modeling study. Sex Transm Dis 2002;29:228-38.
37. Boiry MC, Lowndes CM, Gregson S. Population-level risk factors for HIV transmission and "the 4 Cities Study": temporal dynamics and the significance of sexual mixing patterns. AIDS 2002;16:2101-2.
38. Freeman EE, Weiss HA, Glynn JR, et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006;20:73-83.
39. del Mar Pujades Rodriguez M, Obasi A, Mosha F, et al. Herpes simplex virus type 2 infection increases HIV incidence: a prospective study in rural Tanzania. AIDS 2002;16:451-62.
40. Ramjee G, Williams B, Gouws E, et al. The impact of incident and prevalent herpes simplex virus-2 infection on the incidence of HIV-1 infection among commercial sex workers in South Africa. J Acquir Immune Defic Syndr 2005;39:333-9.
41. Reynolds SJ, Risbud AR, Shepherd ME, et al. Recent herpes simplex virus type 2 infection and the risk of human immunodeficiency virus type 1 acquisition in India. J Infect Dis 2003;187:1513-21.
42. McFarland W, Gwanzura L, Bassett MT, et al. Prevalence and incidence of herpes simplex virus type 2 infection among male Zimbabwean factory workers. J Infect Dis 1999;180:1459-65.
43. Holmberg SD, Stewart JA, Gerber AR, et al. Prior herpes simplex virus type 2 infection as a risk factor for HIV infection. JAMA 1988;259:1048-50.
44. Schacker T, Ryncarz AJ, Goddard J, et al. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA 1998;280:61-6.
45. Mole L, Ripich S, Margolis D, et al. The impact of active herpes simplex virus infection on human immunodeficiency virus load. J Infect Dis 1997;176:766-70.
46. Schacker T, Zeh J, Hu H, et al. Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. J Infect Dis 2002;186:1718-25.
47. Schacker T, Zeh J, Hu HL, et al. Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men. J Infect Dis 1998;178:1616- 22.
48. Wright PW, Hoesley CJ, Squires KE, et al. A prospective study of genital herpes simplex virus type 2 infection in human immunodeficiency virus type 1 (HIV-1)-seropositive women: correlations with CD4 cell count and plasma HIV-1 RNA level. Clin Infect Dis 2003;36:207-11.
49. Mbopi-Keou FX, Gresenguet G, Mayaud P, et al. Interactions between herpes simplex virus type 2 and human immunodeficiency virus type 1 infection in African women: opportunities for intervention. J Infect Dis 2000;182:1090-6.
50. Siegel FP, Lopez C, Hammer GS, et al. Acquired immunodeficiency in male homosexuals manifested by chronic perianal ulcerative herpes simplex lesions. N Engl J Med 1981;305:1439-44.
51. Royce RA, Sena A, Cates W Jr, et al. Sexual transmission of HIV. N Engl J Med 1997;336:1072-8.
52. Cameron DW, Simonsen JN, D'Costa U, et al. Female to male transmission of human immunodeficiency virus type 1 : risk factors for seroconversion in men. Lancet 1989;2:403-7.
53. Mehendale SM, Rodrigues JJ, Brookmeyer RS. Incidence and predictors of human immunodeficiency virus type 1 seroconversion in patients attending sexually transmitted disease clinics in India. J Infect Dis 1995;172:1486-91.
54. Krause P, Straus S. The treatment, management and prevention of genital herpes. In: Stanberry L, eds. Genital and neonatal herpes. 1st edn. Sussex, UK: Wiley, 1996.
55. Puthanakit T, Oberdorfer P, Akarathum N, et al. Immune reconstitution syndrome after HAART in human immunodeficiency virus-infected Thai children. Pediatr Infect Dis J 2006;25:53-8.
56. Ramaswamy M, Sabin C, McDonald C, et al. Herpes simplex virus type 2 (HSV-2) seroprevalence at the time of HIV-1-1. Diagnosis and seroincidence after HIV-1-1. Diagnosis in an ethnically diverse cohort of HIV-1-1-infected persons. Sex Transm Dis 2006;33:96-101.
57. Secular A, Gillespie G, Carman WF. Polymerase chain reaction for diagnosis of genital herpes in a genitourinary medicine clinic. Sex Transm Infect 2002;78:21-5.
58. Ramaswamy M, McDonald C, Smith M, et al. Diagnosis of genital herpes by real time PCR in routine clinical practice. Sex Transm Infect 2004;80:406-10.
59. Geretti AM, Brown DW. National survey of diagnostic services for genital herpes. Sex Transm Infect 2005;81:316-17.
60. Lafferty WE, Krofft S, Remington M, et al. Diagnosis of herpes simplex virus by direct immunofluorescence and viral isolation from samples of external genital lesions in a high-prevalence population. J Clin Microbiol 1987;25:323-6.
61. Slomka MJ, Emery L, Munday PE, et al. A comparison of PCR with virus isolation and direct antigen detection for diagnosis and typing of genital herpes. J Med Virol 1998;55:177-83.
62. Laeyendecker O, Henson C, Gray RH, et al. Performance of a commercial, type-specific enzyme-linked immunosorbent assay for detection of herpes simplex virus type 2-specific antibodies in Ugandans. J Clin Microbiol 2004;42:1794-6.
63. van Dyck E, Buve A, Weiss HA, et al. Performance of commercially available enzyme immunoassays for detection of antibodies against herpes simplex virus type 2 in African populations. J Clin Microbiol 2004;42:2961-5.
64. Celum CL, Robinson NJ, Cohen MS. Potential effect of HIV type 1 antiretroviral and herpes simplex virus type 2 antiviral therapy on transmission and acquisition of HIV type 1 infection. J Infect Dis 2005;191:S107-14.
65. Nilsen AE, Aasen T, Halsos AM, et al. Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes. Lancet 1982;2:571-3.
66. Reichman RC, Badger GJ, Mertz GJ, et al. Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial. JAMA 1984;251:2103-7.
67. Wald A, Corey L. Acyclovir depresses subclinical shedding of herpes simplex virus. Ann Intern Med 1996;125:776-7.
68. World Health Organization. Sources and price of selected drugs and diagnostics for people living with HIV/AIDS. Geneva: WHO, 2002.
69. Schmid G, Steen R, N'Dowa F. Control of bacterial sexually transmitted diseases in the developing world is possible. Clin Infect Dis 2005;41:1313-15.
70. O'Farrell N. Increasing prevalence of genital herpes in developing countries: implications for heterosexual HIV transmission and STD control programmes. Sex Transm Infect 1999;75:377-84.
71. Corey L, Wald A, Patel R, et al. Once daily valaciclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004;350:11-20.
72. Nagot N, Ouedraogo A, Mayaud P, et al. Effect of HSV-2 suppressive therapy on HIV-1 genital shedding and plasma viral load: a proof of concept randomized double-blind placebo controlled trial (ANRS 1285 Trial) [abstract 33LB]. 13th Conference on Retroviruses and Opportunistic Infections, 5-8 February 2006, Denver, Colorado.
73. National Institute of Allergy and Infectious Diseases, National Institutes of Health and Department of Health and Human Services. Workshop summary: scientific evidence on condom effectiveness for sexually transmitted disease (STD) prevention. Herndon, VA: 12-13 June 2000. http://niaid.nih.gov/dmid/stds/ condomreport (accessed 10 Oct 2006).
74. Wald A, Langenberg AG, Link K, et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA 2001;285:3100-6.
75. Wald A, Langenberg AG, Krantz E, et al. The relationship between condom use and herpes simplex virus acquisition. Ann Intern Med 2005;143:707-13.
76. Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002;347:1652-61.
77. Corey L, Langenberg AG, Ashley R, et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection; two randomized controlled trials. JAMA 1999;281:331-40.